Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 91, Issue 2, 2003, Pages 160-167

  Chervinsky, Paul ^a   Casale, Thomas ^b   Townley, Robert ^b   Tripathy, Ita ^c   Hedgecock, Simon ^d   Fowler Taylor, Angel ^e   Shen, Henry ^e   Fox, Howard ^d  

^a Northeast Medical Research Associates   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Clinical Research of the Ozarks   (United States)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; PLACEBO;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; APPENDICITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INFECTIOUS MONONUCLEOSIS; INTERVERTEBRAL DISK HERNIA; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; PERENNIAL RHINITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; RHINOPHARYNGITIS; SCHOOL CHILD; SEASONAL VARIATION; SERUM SICKNESS; SYMPTOMATOLOGY; SYNCOPE; TREATMENT OUTCOME; TREATMENT PLANNING; URTICARIA;

EID: 0041737745     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62171-0     Document Type: Article

References (22)

1. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol. 2001;107:3-8.
2. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol. 1998;81:478-518.
3. Juniper EF. Impact of upper respiratory allergic diseases on quality of life. J Allergy Clin Immunol. 1998;101:S386-S391.
4. Blanc PD, Trupin L, Eisner M, et al. The work impact of asthma and rhinitis: findings from a population-based survey. J Clin Epidemiol. 2001;54:610-618.
5. Simons FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc. 1996;17:185-189.
6. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108:S2-S8.
7. Scadding GK, Richards DH, Price MJ. Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. Clin Otolaryngol. 2000;25:551-557.
8. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001;286:2956-2967.
9. Ädelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106:253-259.
10. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108: 184-190.
11. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics, Eur Respir J. 2001;18:254-261. [Erratum in Eur Respir J. 2001;18:739-740].
12. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36. [Full text available at www.pediatrics.org/cgi/content/full/108/2/e36].
13. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77-83.
14. Juniper EF, Guyatt GH, Andersson B, Ferrie PJ. Comparison of powder and aerosolized budesonide in perennial rhinitis: validation of rhinitis quality of life questionnaire. Ann Allergy. 1993;70:225-230.
15. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 1996;98:843-845.
16. Juniper EF. Quality of life in adults and children with asthma and rhinitis. Allergy. 1997;52:971-977.
17. Bousquet J, Van Cauwenberge P, Khaltaev N. ARIA Workshop Group. World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(Suppl):S147-S334.
18. Welch MJ, Bronsky EA, Grossman J, et al. Clinical evaluation of triamcinolone acetonide nasal aerosol in children with perennial allergic rhinitis. Ann Allergy. 1991;67:493-498.
19. Amat P, Novella A, Roma J, Valero A, Lluch M, Malet A. Treatment of perennial allergic rhinitis with cetirizine. Allergol Immunopathol. 1992;20:139-143.
20. Davies RJ, Lund VJ, Harten-Ash VJ. The effect of intranasal azelastine and beclomethasone on the symptoms and signs of nasal allergy in patients with perennial allergic rhinitis. Rhinology. 1993;31:159-164.
21. Bende M, Carrillo T, Vona I, da Castel-Branco MG, Arheden L. A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2002;88:617-623.
22. Buhl R, Solèr M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002;20:73-78.